Long-term outcomes of pars plana Ahmed valve implant and vitrectomy in eyes with refractory glaucoma.
anti-glaucoma agent
glaucoma drainage implant
intraocular pressure
neovascular glaucoma
pars plana
Journal
Medical hypothesis, discovery & innovation ophthalmology journal
ISSN: 2322-3219
Titre abrégé: Med Hypothesis Discov Innov Ophthalmol
Pays: United States
ID NLM: 101611331
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
04
2022
accepted:
30
04
2022
medline:
30
4
2022
pubmed:
30
4
2022
entrez:
29
8
2023
Statut:
epublish
Résumé
Pars plana vitrectomy with implantation of an Ahmed glaucoma valve in the vitreous cavity has been reported with a success rate in the management of refractory and neovascular glaucoma. This study aimed to present the outcomes of pars plana Ahmed glaucoma valve (PPAV) surgical implantation in cases with refractory glaucoma. In this single-center, retrospective, comparative study, 87 consecutive patients diagnosed with refractory glaucoma who underwent PPAV surgical implantation between October 2015 and October 2019 were evaluated. A successful postoperative outcome was defined as intraocular pressure (IOP) ≤ 21 mmHg upon examination and a reduction in the number of anti-glaucoma agents used at the latest follow-up. Finally, 81 eyes of 78 patients with refractory glaucoma were included; 54 (66.66%) of the eyes had neovascular glaucoma. The mean follow-up was 20.65 ± 12.17 months (range: 2-52 months). The mean preoperative IOP was 40.01 ± 1.19 mmHg and reduced significantly to 16.73 ± 0.82 mmHg at the latest follow-up ( PPAV surgery is a successful procedure for IOP reduction in patients with refractory glaucoma. Our study demonstrated either reduction or elimination of IOP lowering eye drops postoperatively. Large scale studies with a comparison group, a longer follow-up, and having various subtypes of glaucoma are required as future research to confirm these outcomes.
Sections du résumé
Background
UNASSIGNED
Pars plana vitrectomy with implantation of an Ahmed glaucoma valve in the vitreous cavity has been reported with a success rate in the management of refractory and neovascular glaucoma. This study aimed to present the outcomes of pars plana Ahmed glaucoma valve (PPAV) surgical implantation in cases with refractory glaucoma.
Methods
UNASSIGNED
In this single-center, retrospective, comparative study, 87 consecutive patients diagnosed with refractory glaucoma who underwent PPAV surgical implantation between October 2015 and October 2019 were evaluated. A successful postoperative outcome was defined as intraocular pressure (IOP) ≤ 21 mmHg upon examination and a reduction in the number of anti-glaucoma agents used at the latest follow-up.
Results
UNASSIGNED
Finally, 81 eyes of 78 patients with refractory glaucoma were included; 54 (66.66%) of the eyes had neovascular glaucoma. The mean follow-up was 20.65 ± 12.17 months (range: 2-52 months). The mean preoperative IOP was 40.01 ± 1.19 mmHg and reduced significantly to 16.73 ± 0.82 mmHg at the latest follow-up (
Conclusions
UNASSIGNED
PPAV surgery is a successful procedure for IOP reduction in patients with refractory glaucoma. Our study demonstrated either reduction or elimination of IOP lowering eye drops postoperatively. Large scale studies with a comparison group, a longer follow-up, and having various subtypes of glaucoma are required as future research to confirm these outcomes.
Identifiants
pubmed: 37641700
doi: 10.51329/mehdiophthal1445
pmc: PMC10445320
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44-51Informations de copyright
© Author(s).
Déclaration de conflit d'intérêts
None.
Références
Eye (Lond). 2017 Apr;31(4):608-614
pubmed: 27983734
Ophthalmic Surg Lasers Imaging. 2007 Jul-Aug;38(4):292-300
pubmed: 17674919
Ophthalmology. 2006 Jun;113(6):913-7
pubmed: 16751034
Br J Ophthalmol. 2010 Sep;94(9):1174-9
pubmed: 19965829
BMC Ophthalmol. 2018 Aug 29;18(1):212
pubmed: 30157805
Curr Opin Ophthalmol. 2004 Apr;15(2):119-26
pubmed: 15021223
BMC Ophthalmol. 2015 Dec 12;15:176
pubmed: 26653326
Korean J Ophthalmol. 2005 Dec;19(4):293-6
pubmed: 16491820
Am J Ophthalmol. 2007 Jan;143(1):23-31
pubmed: 17054896
J Glaucoma. 2017 Jun;26(6):e190-e193
pubmed: 28263264
Int J Ophthalmol. 2020 May 18;13(5):832-836
pubmed: 32420233
J Ophthalmol. 2018 May 10;2018:9572805
pubmed: 29862068
Beyoglu Eye J. 2019 Aug 19;4(2):115-119
pubmed: 35187444
Clin Ophthalmol. 2010 May 06;4:411-6
pubmed: 20463912
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Clin Exp Ophthalmol. 2012 May-Jun;40(4):341-9
pubmed: 22356435
Cornea. 2015 Jan;34(1):37-41
pubmed: 25393097
Korean J Ophthalmol. 2012 Dec;26(6):432-7
pubmed: 23204798
Eur J Ophthalmol. 2012 Jul-Aug;22(4):667-9
pubmed: 22034023
Int J Ophthalmol. 2013 Jun 18;6(3):316-20
pubmed: 23826525
J Glaucoma. 2015 Feb;24(2):95-9
pubmed: 23787335
Indian J Ophthalmol. 2011 Jan;59 Suppl:S123-30
pubmed: 21150024
Indian J Ophthalmol. 2010 Sep-Oct;58(5):440-2
pubmed: 20689206
J Glaucoma. 2013 Dec;22(9):750-6
pubmed: 24304908
Saudi J Ophthalmol. 2018 Jul-Sep;32(3):180-187
pubmed: 30224880
Niger J Med. 2012 Jan-Mar;21(1):78-80
pubmed: 23301454
Eur J Ophthalmol. 2017 Nov 8;27(6):774-780
pubmed: 28430329
Nippon Ganka Gakkai Zasshi. 2008 Jun;112(6):511-8
pubmed: 18592974
Int J Ophthalmol. 2021 Sep 18;14(9):1396-1401
pubmed: 34540616
Ophthalmic Surg Lasers. 2002 Sep-Oct;33(5):383-93
pubmed: 12358292
J Ophthalmol. 2015;2015:486832
pubmed: 25694824
Jpn J Ophthalmol. 2012 Mar;56(2):119-27
pubmed: 22203463
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
J Glaucoma. 2021 Apr 1;30(4):362-367
pubmed: 33273285
Clin Ophthalmol. 2017 Feb 17;11:357-367
pubmed: 28255226
Korean J Ophthalmol. 2012 Apr;26(2):92-6
pubmed: 22511834
Adv Ther. 2017 Apr;34(4):834-847
pubmed: 28283892
Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):336-41
pubmed: 16133027
Retina. 2013 Nov-Dec;33(10):2059-68
pubmed: 23609124
Br J Ophthalmol. 2000 Jul;84(7):718-21
pubmed: 10873981
Middle East Afr J Ophthalmol. 2020 Apr 29;27(1):40-46
pubmed: 32549723
Sci Rep. 2021 Jun 21;11(1):12986
pubmed: 34155282